Array BioPharma v. Eugia Pharma: Braftovi® Patent Consent Judgment in 126 Days
Array BioPharma filed suit in the Delaware District Court against Eugia Pharma Specialities and Aurobindo Pharma USA over US9474754, covering encorafenib capsules marketed as Braftovi®, a B-RAF inhibitor combination therapy. The case resolved via consent judgment within 126 days, triggered by Eugia's mid-litigation switch from a Paragraph IV to a Section VIII certification.
ANDA Paragraph IV challenge resolved in under four months via consent judgment
Array BioPharma, Inc. — holder of NDA No. 210496 for encorafenib capsules sold as Braftovi® — filed suit on September 22, 2022 in the U.S. District Court for the District of Delaware against Eugia Pharma Specialities Limited and Aurobindo Pharma USA, Inc. The action was triggered by Eugia's Paragraph IV certification as part of ANDA No. 217609, challenging the validity and/or non-infringement of Orange Book-listed US9474754, which expires August 5, 2033. Filing within 45 days of receiving Eugia's August 2022 Paragraph IV notice automatically imposed a 30-month FDA approval stay under the Hatch-Waxman Act.
The case ended on January 26, 2023, when the parties filed a stipulation that the court entered as a consent judgment. The recorded basis of termination is Consent Judgment; the docket order is styled as a stipulated dismissal without prejudice of Plaintiff's claims. The resolution was precipitated by Eugia's January 10, 2023 notification that it had converted its Paragraph IV certification to a Section VIII certification with respect to US9474754, removing the patent from ANDA No. 217609's challenge. Each party bears its own costs and fees. The District of Delaware retains jurisdiction to resolve any disputes arising under the stipulation.
The 126-day resolution is notably swift for Hatch-Waxman ANDA litigation, which typically spans years. The pivot to a Section VIII certification — which carves around rather than challenges the listed patent — suggests Eugia elected to reformulate or restrict its product labelling to avoid the '754 patent's claims rather than litigate validity or infringement to judgment. A conditional provision in the stipulation allows Plaintiff to seek reinstatement of the 30-month stay if Eugia reverts to a Paragraph IV certification in the future. The specific commercial terms underlying the parties' agreement are not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 126 days
126 days — resolved well below the median Hatch-Waxman ANDA litigation duration
US9474754 — encorafenib B-RAF inhibitor combination therapy
Any company developing, filing an ANDA for, or commercialising encorafenib capsules or B-RAF/EGFR inhibitor combination therapies should treat US9474754 as a priority FTO target. The patent's broad combination claim scope — covering B-RAF inhibitor, EGFR inhibitor, and PI3K-α inhibitor combinations — means that formulation or label differences alone may not be sufficient to design around. With the patent active through August 2033 and the Orange Book listing intact, the risk of triggering a 30-month FDA stay is real for any Paragraph IV filer in this space.
Official order — verbatim text
The stipulation records Eugia's mid-litigation conversion from a Paragraph IV to a Section VIII certification as the operative trigger for resolution. No merits determination on the validity or infringement of US9474754 was reached. The court's retained jurisdiction clause and the conditional 30-month stay provision are the legally significant operative terms, preserving Array's enforcement position if Eugia reverts to a Paragraph IV challenge on ANDA No. 217609.
Consent judgment: what the agreed resolution means for both parties
Consent judgment: a binding, court-entered resolution
A consent judgment is a formal court-entered judgment reflecting terms agreed between the parties. It is not merely a private settlement — it carries the legal force of a court judgment and is enforceable as such. Here, the District of Delaware expressly retained jurisdiction to resolve any dispute arising under the stipulation, reinforcing the binding nature of the agreed terms. The underlying docket order is styled as a dismissal without prejudice, but the recorded basis of termination is Consent Judgment.
Court-entered, enforceable judgmentArray's Orange Book patent survives unchallenged
Eugia's conversion to a Section VIII certification removes US9474754 from active challenge in ANDA No. 217609. Array's patent — expiring August 2033 — remains listed in the Orange Book and unadjudicated on the merits. The consent judgment includes a prospective protection clause: if Eugia reverts to a Paragraph IV certification, it must issue a new notice and, if Array sues timely, cannot contest imposition of a new 30-month FDA stay. Array retains meaningful enforcement leverage through 2033.
Patent unadjudicated — protection retainedEugia exits litigation via Section VIII carve-around
By converting to a Section VIII certification, Eugia signals it has restructured its ANDA to avoid the '754 patent's scope — typically through label carve-outs that exclude patented indications. This ends the immediate litigation without a merits ruling on invalidity or non-infringement, preserving the option to return to a Paragraph IV challenge in the future, subject to the stipulation's notice requirements. The commercial and labelling implications of the Section VIII approach are not disclosed in the available record.
Label carve-out strategy; no merits rulingHatch-Waxman carve-out dynamics in oncology generics
This case illustrates a well-recognised Hatch-Waxman dynamic: a generic challenger may exit patent litigation by narrowing its ANDA through a Section VIII carve-out rather than litigating to judgment. For competitors in the encorafenib space, US9474754 remains an active Orange Book barrier through August 2033. The outcome reinforces that early-stage ANDA certification strategy — Paragraph IV vs. Section VIII — can be pivotal in determining whether litigation proceeds. Other ANDA filers for encorafenib should conduct careful FTO analysis against the '754 patent.
Orange Book barrier intact through 2033Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Array BioPharma, Inc. | Company | Oncology pharma — holder of US9474754 for encorafenib (Braftovi®) B-RAF inhibitorSearch in Eureka ↗ |
| Defendant | Eugia Pharma Specialities Limited | Company | Generic pharmaceutical manufacturer (Eugia/Aurobindo) pursuing ANDA No. 217609 for encorafenib capsulesSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Array BioPharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Array BioPharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Array BioPharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Carl Douglas Neff | Attorney | Counsel for Eugia Pharma Specialities LimitedSearch in Eureka ↗ |
| Defendant counsel | Gongjun Ji | Attorney | Counsel for Eugia Pharma Specialities LimitedSearch in Eureka ↗ |
| Defendant counsel | Gurpreet S. Walia | Attorney | Counsel for Eugia Pharma Specialities LimitedSearch in Eureka ↗ |
| Defendant law firm | FisherBroyles LLP | Law Firm | Representing Eugia Pharma Specialities LimitedSearch in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the B-RAF inhibitor and oncology combination therapy space
Forward-looking patent and R&D intelligence derived from this case — covering Array's portfolio, encorafenib filing trends, Aurobindo's IP posture, and white-space opportunities in BRAF-targeted combination therapy.
Array BioPharma's B-RAF inhibitor patent estate beyond US9474754
US9474754 is one node in what may be a broader patent family protecting encorafenib and its combinations. Array — now part of Pfizer — may hold continuation, divisional, or method-of-use patents covering dosing regimens, formulations, or specific indication combinations that extend beyond the base compound claims. Mapping the full portfolio is essential for any ANDA filer or combination therapy developer operating in the BRAF-mutant cancer space.
Array / Pfizer portfolio depthBRAF + EGFR inhibitor combination therapy filing trends
The combination of B-RAF and EGFR inhibitors is a growing area of oncology patent activity, particularly for BRAF V600E-mutant colorectal and melanoma indications. Filing trends in this space — covering novel combinations, resistance mechanisms, and companion diagnostics — signal where the next wave of exclusivity disputes may emerge. Companies active in targeted oncology should monitor continuation filings in IPC class A61K31 and related combination therapy subclasses.
BRAF/EGFR combo filing trendsAurobindo / Eugia's patent and ANDA strategy in oncology generics
Aurobindo Pharma and its subsidiary Eugia are active ANDA filers in complex oncology generics. Their decision to shift from Paragraph IV to Section VIII certification in this case reflects an adaptive IP strategy. Tracking Eugia's ANDA filings and any patent applications in the oncology small-molecule space can reveal competitive positioning and potential future challenge targets across the B-RAF inhibitor and related kinase inhibitor product categories.
Eugia/Aurobindo oncology ANDA posturePI3K-α inhibitor combinations: adjacent innovation space near US9474754
US9474754 optionally incorporates PI3K-α inhibitors in its combination claims, suggesting the inventors anticipated triple-combination regimens. The PI3K pathway remains an active R&D frontier for BRAF-mutant cancers. Patent white-space analysis around novel PI3K-α inhibitor combinations — particularly those not covered by the existing BRAF/EGFR claim architecture — may reveal formulation, dosing, or biomarker opportunities available for independent patent protection.
PI3K-α combo white spaceSimilar Hatch-Waxman ANDA cases involving B-RAF inhibitor patents
Explore related Hatch-Waxman ANDA patent infringement cases in the oncology small-molecule space, litigated in the Delaware District Court.
What this case signals for the oncology generics IP landscape
A swift Hatch-Waxman exit via Section VIII carve-out leaves US9474754 intact and sets a procedural precedent for encorafenib ANDA filers.
US9474754 remains an active Orange Book barrier through August 2033
Eugia's pivot to a Section VIII certification removed the patent from active challenge without any merits adjudication. For ANDA filers and generic manufacturers eyeing encorafenib, the '754 patent remains fully in force and Orange Book-listed. Any future Paragraph IV filer must be prepared for the automatic 30-month stay and potential litigation.
Section VIII carve-outs can collapse litigation in weeks — not years
This case resolved in 126 days — well below the typical multi-year Hatch-Waxman timeline. The key driver was Eugia's mid-case decision to restructure its ANDA. Litigation counsel and in-house IP teams should model the Section VIII carve-out option early, before filing costs and discovery commitments accumulate. The conditional 30-month stay clause in the stipulation also signals Array's intent to enforce aggressively against any reversion.
Array v Eugia — key questions answered
The recorded basis of termination is Consent Judgment. The parties filed a joint stipulation on January 26, 2023 that was entered by the Delaware District Court. The docket order is styled as a dismissal without prejudice of Plaintiff's claims, with each party bearing its own costs. The court retained jurisdiction to resolve any disputes arising under the stipulation.
Array BioPharma filed suit because Eugia submitted ANDA No. 217609 for encorafenib capsules with a Paragraph IV certification challenging the validity and/or non-infringement of US9474754 — the Orange Book-listed patent for Braftovi®. Under the Hatch-Waxman Act, Array was required to file within 45 days of receiving Eugia's Paragraph IV notice to trigger the automatic 30-month FDA approval stay, which it did.
A Section VIII certification is a statement by an ANDA applicant that it is not seeking approval for a patented use listed in the Orange Book — effectively a label carve-out. By converting from Paragraph IV to Section VIII on January 10, 2023, Eugia removed the direct challenge to US9474754, which ended the litigation. The specific commercial or formulation reasons for Eugia's decision are not disclosed in the available record.
No. The consent judgment contains no merits determination on the validity or infringement of US9474754. The patent was neither upheld nor invalidated by the court. The case resolved purely on procedural and certification grounds following Eugia's switch to a Section VIII certification. US9474754 remains in force and Orange Book-listed through August 5, 2033.
The stipulation includes a conditional clause: if Eugia converts its Section VIII certification back to a Paragraph IV certification, it must send a new Paragraph IV notice to Array. If Array timely files suit, Eugia has agreed not to contest imposition of a new 30-month FDA stay of final approval for ANDA No. 217609 under 21 U.S.C. § 355(j)(5)(B)(iii). This provision gives Array meaningful forward-looking enforcement leverage.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.